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Biochemistry 
Peroxo-iron and oxenoid-iron species as alternative oxygenating 
agents in cytochrome P450-catalyzed reactions: Switching by 
Threonine-302 to Alanine mutagenesis of cytochrome P450 2B4 
ALFIN D. N. VAZ*, STEVEN J. PERNECKYt, GREGORY M. RANER, AND MINOR J. COON 
Department of Biological Chemistry, Medical School, University of Michigan, Ann Arbor, MI 48109 
Contributed by Minor J. Coon, January 16, 1996 
ABSTRACT Among biological catalysts, cytochrome 
P450 is unmatched in its multiplicity of isoforms, inducers, 
substrates, and types of chemical reactions catalyzed. In the 
present study, evidence is given that this versatility extends to 
the nature of the active oxidant. Although mechanistic evi- 
dence from several laboratories points to a hypervalent iron- 
oxenoid species in P450-catalyzed oxygenation reactions, 
Akhtar and colleagues [Akhtar, M., Calder, M. R., Corina, 
D. L. & Wright, J. N. (1982) Biochem. J. 201, 569-580] proposed 
that in steroid deformylation effected by P450 aromatase an 
iron-peroxo species is involved. We have shown more recently 
that purified liver microsomal P450 cytochromes, including 
phenobarbital-induced P450 2B4, catalyze the analogous de- 
formylation of a series of xenobiotic aldehydes with olefin 
formation. The investigation presented here on the effect of 
site-directed mutagenesis of threonine-302 to alanine on the 
activities of recombinant P450 2B4 with N-terminal amino 
acids 2-27 deleted [2B4 (A2-27)] makes use of evidence from 
other laboratories that the corresponding mutation in bacte- 
rial P450s interferes with the activation of dioxygen to the 
oxenoid species by blocking proton delivery to the active site. 
The rates of NADPH oxidation, hydrogen peroxide produc- 
tion, and product formation from four substrates, including 
formaldehyde from benzphetamine N-demethylation, aceto- 
phenone from 1-phenylethanol oxidation, cyclohexanol from 
cyclohexane hydroxylation, and cyclohexene from cyclohexane 
carboxaldehyde deformylation, were determined with P450s 
2B4, 2B4 (A2-27), and 2B4 (A2-27) T302A. Replacement of 
the threonine residue in the truncated cytochrome gave a 1.6- 
to 2.5-fold increase in peroxide formation in the presence of a 
substrate, but resulted in decreased product formation from 
benzphetamine (9-fold), cyclohexane (4-fold), and 1-phenyl- 
ethanol (2-fold). In sharp contrast, the deformylation of cyclo- 
hexane carboxaldehyde by the T302A mutant was increased 
about 10-fold. On the basis of these findings and our previous 
evidence that aldehyde deformylation is supported by added 
H202, but not by artificial oxidants, we conclude that the 
iron-peroxy species is the direct oxygen donor. It remains to 
be established which of the many other oxidative reactions 
involving P450 utilize this species and the extent to which 
peroxo-iron and oxenoid-iron function as alternative oxygen- 
ating agents with the numerous isoforms of this versatile 
catalyst. 
The cytochrome P450 (P450) gene superfamily includes nu- 
merous hemoproteins involved in the metabolism of steroid 
hormones, vitamins, retinoids, eicosanoids, and other physio- 
logically occurring compounds, as well as of an almost unlim- 
ited variety of drugs, pesticides, carcinogens, and other xeno- 
biotics (1). These versatile catalysts are thought to use as an 
active oxidant a hypervalent iron-oxenoid species comparable 
The publication costs of this article were defrayed in part by page charge 
payment. This article must therefore be hereby marked "advertisement" in 
accordance with 18 U.S.C. ?1734 solely to indicate this fact. 
to compound I of peroxidases (2-5). Although the identity of 
this oxidant in P450-catalyzed reactions has not been rigor- 
ously established, mechanistic evidence points to the involve- 
ment of such a species in hydroxylation reactions and other 
transformations catalyzed by these enzymes (5, 6). However, in 
examining the terminal step in steroid demethylation catalyzed 
by P450 aromatase, Akhtar and colleagues (7) observed that 
the pattern of isotopic label distribution and the incorporation 
of an oxygen atom from molecular oxygen into the products 
was inconsistent with an oxenoid oxidant. Furthermore, they 
hypothesized that the active oxidant in the aromatase- 
catalyzed carbon-carbon bond cleavage step and related 
reactions effected by lanosterol 14a-demethylase, progester- 
one 17,20-lyase, and pregnenolone 17,20-lyase-A16-desaturase 
was a nucleophilic, iron-peroxo species (7, 8). Subsequently, 
other investigators (9-12) proposed a similar intermediate, 
and our laboratory (13, 14) showed that purified isoforms of 
liver microsomal P450 catalyze the oxidative deformylation of 
a variety of xenobiotic aldehydes to olefins and formate, a 
reaction comparable in functional group transformation tothe 
terminal carbon-carbon bond cleavage step catalyzed by 
aromatase and lanosterol 14a-demethylase. Consistent with an 
iron-peroxo species as the active oxidant in this reaction was 
the demonstration that of several agents known to support 
many P450-catalyzed reactions in the absence of 02 and 
NADPH, H202 was capable of supporting olefin formation in 
the oxidative deformylation of cyclohexane carboxaldehyde, 
but iodosobenzene, m-chloroperbenzoic acid, and cumyl hy- 
droperoxide were not (14). More recently, a bicyclic steroid 
analog, 3-oxodecalin-4-ene-10-carboxaldehyde, which corre- 
sponds to the A and B rings of the 19-oxo androgen interme- 
diate in the aromatase reaction, has been shown to be oxidized 
to formate and the expected aromatic product, 3-hydroxytet- 
rahydronaphthalene, with the same stereochemical specificity 
as in the terminal step of the aromatase-catalyzed reaction (15, 
16). The iron-peroxo concept has recently been extended to the 
nitric oxide-generating step in the reaction of nitric oxide 
synthase (17). It may be noted that the iron-peroxo and 
iron-oxenoid species are fundamentally distinct oxidants, the 
former being nucleophilic and the latter electrophilic in char- 
acter. 
In this paper we have used site-specific mutagenesis of P450 
2B4 (rabbit liver) (2B4) to determine amino acid residues at 
the active site that may control the relative extent of the 
oxenoid and peroxo pathways. The extensive crystallographic 
and mutagenic studies on bacterial P450cam and sequence 
homology alignments with numerous mammalian P450s 
served to identify threonine-302 of P450 2B4 as a candidate for 
Abbreviations: P450, cytochrome P450; 2B4, P450 2B4 (rabbit liver); 
2B4 (A2-27), recombinant P450 2B4 with N-terminal amino acids 2-27 
deleted; 2B4 (A2-27) T302A, truncated P450 2B4 with threonine-302 
mutated to alanine. 
*To whom reprint requests should be addressed. 
tPresent address: Department of Chemistry, Eastern Michigan Uni- 
versity, Ypsilanti, MI 48197. 
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mutagenesis in this study. Raag et al. (18) have evaluated an 
earlier proposal on hydrogen bonding (19) and have discussed 
oxygen activation in light of two potential pathways identified 
for proton delivery to the active site via an internal solvent 
channel between threonine-252 and glutamate-366 or through 
a hydrogen bonding network extending from the surface of the 
protein to the heme environment. Although a crystal structure 
of oxygen bound to P450Cam has not been determined, molec- 
ular modeling places threonine-252 in bonding distance to the 
putative heme dioxygen complex, and this residue has been 
postulated to play a role in the activation of dioxygen to the 
oxenoid species by serving as a link for proton delivery to the 
active site (18, 19). In support of such a role for threonine-252 
in the catalytic cycle of P450cam, its mutation to valine or 
alanine resulted in a protein essentially devoid of camphor 
hydroxylation activity, whereas neither substrate binding nor 
the rate of the first electron transfer to the heme center was 
affected. The uptake of reducing equivalents from NADH was 
largely uncoupled from substrate hydroxylation and resulted in 
the nonproductive formation of H202 or H20 as shown by 
Martinis et al. (20) and Imai et al. (21). More recently, Kimata 
et al. (22) have replaced T252 in P450cam by the unnatural 
amino acid O-methylthreonine. The mutation resulted in a 
protein that was identical to the wild-type enzyme in its 
catalytic properties, suggesting that T252 does not function 
directly as a proton donor. The possibility remains, however, 
that the altered residue had undergone 0-demethylation. 
From sequence homology alignments a highly conserved 
threonine corresponding to that in position 252 of P450cam has 
been identified in most known P450 sequences, an exception 
being P450EryF, which has a valine instead (23-26). The 
conserved threonine of several mammalian P450 isoforms has 
been mutated to examine its role in catalysis. For example, 
replacement of threonine-301 by histidine or valine in rabbit 
liver laurate (w-1) hydroxylase and testosterone 16a-hydrox- 
ylase P450s caused a significant loss of hydroxylation activity 
by these enzymes (27, 28), and mutagenesis of threonine-319 
of P450 1A2 resulted in loss of activity in benzphetamine 
demethylation but not in 7-ethoxycoumarin 0-deethylation 
(29, 30). Recently the mutation of threonine-268 of P450BM-3 
has been shown to result in no significant alteration of the 
heme domain structure (31). However, the rates of NADPH 
oxidation and oxygen consumption are decreased, and a 
significant loss in laurate hydroxylation activity with uncou- 
pling to produce H202 and H:20 has been noted. The heme 
domain of this P450 has significantly more sequence homology 
than P450cam with respect to the microsomal P450s (32). 
Because the oxidative deformylation of various xenobiotic 
aldehydes to yield olefins and formate is believed to involve the 
iron-peroxo intermediate as the active oxidant, we postulated 
that disruption of the pathway leading from the iron-peroxo 
to the iron-oxene species should result in loss of oxenoid- 
dependent hydroxylation chemistry and enhancement of iron- 
peroxo-dependent reactions. We have briefly reported our 
findings on this problem (33, 34), and herein we present our 
studies involving the mutagenesis of the conserved threonine 
(T302) to alanine in the P450 2B4 sequence. The results 
indicate that the hydroxylation of several substrates is greatly 
diminished by this mutation, but that the deformylation- 
desaturation reaction is strikingly enhanced. 
MATERIALS AND METHODS 
Materials. Electrophoretically homogeneous P450 2B4 
(specific content, 15.4 nmol per mg of protein) and NADPH- 
cytochrome P450 reductase (specific activity, 30.2 units per mg 
at 30?C) were obtained from liver microsomes of male New 
Zealand rabbits that had been treated with phenobarbital, as 
described (35, 36). Analytical grade reagents were obtained 
commercially and used as such unless otherwise indicated. 
Cloning and Heterologous Expression of NH2-Terminal- 
Truncated P45Os. Shortened P450 2B4 and the truncated P450 
2B4 with threonine-302 mutated to alanine (2B4 (A2-27) 
T302A), both lacking residues 2-27, were expressed in Esch- 
erichia coli as fusion proteins with glutathione S-transferase 
linked to the NH2 terminus of the cytochrome. The vectors 
used were constructed from the Pharmacia vector pGEX-KN 
modified to include a kinker region encoding a sequence that 
improves the efficiency of thrombin cleavage of the fusion 
protein. The 2B4 (A2-27) clone was constructed as described 
by Pernecky et al. (37). Threonine-302 was changed by the PCR 
method to alanine; the 5' amplification primer (GC AAG CTT 
GCC GGC ACC GAG GCC ACC AGC ACC ACC C) ex- 
tending from positions 892 to 919 in the cDNA sequence of 
2B4 (38) contained an A to G substitution at position 904 to 
produce the desired mutation and an Nael site for cloning into 
the vector. The first eight nucleotides (GCAAGCTT), which 
are not in the 2B4 gene sequence, were present to improve the 
cutting efficiency of Nael. The PCR product was digested with 
Nael and Rsrll and cloned into the similarly digested shortened 
2B4 construct to obtain 2B4 (A2-27) T302A. The DNA 
sequence of this region was determined to ensure fidelity of the 
Taq DNA polymerase during the reaction. The proteins were 
expressed in E. coli MV1304 cells as described (37). Typical 
yields of the recombinant proteins were from 50 to 300 nmol 
of P450 per liter of culture. For purification of the fusion 
proteins, the harvested cells were suspended in 30 mM potas- 
sium phosphate buffer, pH 7.4, containing 150 mM NaCl, 20% 
glycerol, and 0.1% 2-mercaptoethanol (PBS), and then treated 
with n-octyl f-D-glucopyranoside (1% final concentration) 
with stirring for 20 min and lysed by two passes in a French 
pressure cell. All procedures were carried out at room tem- 
perature unless otherwise stated. The lysate was diluted with 
1 vol of PBS and centrifuged at 140,000 x g to remove insoluble 
components. The clear supernatant fraction was applied to a 
glutathione-agarose column (40 nmol of P450 per ml of bed 
volume) that had been equilibrated with PBS containing 0.3% 
octyl glucoside (PBSO). The matrix was washed with 10 
column vol of 100 mM Tris Cl buffer, pH 7.4, containing 120 
mM NaCl, 20% glycerol, and 0.3% octyl glucoside (TBSO). 
The contents of the column were then extruded, and the fusion 
protein was eluted from the matrix by stirring at 4?C overnight 
with an equal volume of TBSO buffer containing 20 mM 
glutathione and then several times for about 1 h with an equal 
volume of the same buffer. The pooled eluate was dialyzed 
against Tris-buffered saline (TBS) to remove glutathione and 
the detergent, and the fusion protein was treated at room 
temperature for 36 h with 8 units of thrombin per nmol of 
P450. The mixture was then passed over a glutathione-agarose 
column to remove glutathione S-tranferase and any remaining 
uncleaved fusion protein. The purified material was concen- 
trated by dialysis overnight at 4?C against 2 liters of 100 mM 
potassium phosphate (pH 7.4), containing 20% glycerol and 
0.1 mM EDTA, in a ProDicon concentrator (Spectrum Lab- 
oratories, Houston) to yield preparations that had a specific 
content of from 7.2 to 11.2 nmol of P450 per mg of protein. 
Enzymatic Reactions and Analytical Procedures. A typical 
reaction mixture contained 0.1 nmol of P450 2B4, 2B4 (A2- 
27), or 2B4 (A2-27) T302A (except that when aldehyde 
deformylation was to be determined the amount of P450 was 
0.2 nmol and 100 units of catalase and 50 units of superoxide 
dismutase were included), 0.2 nmol of reductase, 30 ,ug of 
dilauroylglycerol-3-phosphocholine, 100 ,umol of potassium 
phosphate buffer (pH 7.4), substrate (1.0 ,umol of benzphet- 
amine, cyclohexane, or cyclohexane carboxaldehyde, or 10 
,umol of 1-phenylethanol) in a final volume of 1.0 ml. All 
reactions were initiated by the addition of 0.15 ,umol of 
NADPH and carried out at 30?C, except that the conversion of 
cyclohexane carboxaldehyde to cyclohexene was determined at 
37?C. Formaldehyde formed from benzphetamine was mea- 
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Table 1. Rates of NADPH oxidation and hydrogen peroxide formation by P450 2B4 and variants in 
the reconstituted enzyme system 
NADPH oxidation, nmol/min H202 formation, nmol/min 
per nmol of P450 per nmol of P450 
2B4 2B4 
2B4 (A2-27) 2B4 (A2-27) 
Substrate 2B4 (A2-27) T302A 2B4 (A2-27) T302A 
None 16+1 10+1 16+1 9+1 9+1 10?1 
Benzphetamine 121 6 40 1 42 1 26 3 13 1 32 3 
1-Phenylethanol 38 2 18 2 25 1 16 2 11 1 22 1 
Cyclohexane 52 2 24 1 25 1 19 2 13 1 21 1 
Cyclohexane carboxaldehyde 59 + 2 21 + 1 33 + 1 50 ? 1 8 + 1 18 I 1 
sured by the method of Cochin and Axelrod (39) and aceto- 
phenone formed from 1-phenylethanol was analyzed by re- 
versed-phase HPLC as described by Vaz and Coon (40). 
Cyclohexanol formed from cyclohexane was analyzed by gas 
chromatography as follows: the reactions were quenched by 
the addition of 0.2 ml of 1 M NaOH, and 1.0 ymol of 1-hexanol 
was added as an internal standard. The reaction mixture was 
extracted with 2.0 ml of chloroform, the extract was concen- 
trated to approximately 50 yl under reduced pressure in a 
vacuum centrifuge, and 1.0 yl of the residual solution was 
injected onto a 6-ft Supelco 60/80 Carbopack B column 
containing 4% Carbowax 20M and 0.8% KOH, operated under 
isothermal conditions at 160?C. The carrier gas was nitrogen 
at a flow rate of 22 ml/min. Under these conditions cyclo- 
hexanol was eluted at 8 min and the internal standard at 13 
min. The integrated peak areas for cyclohexanol and 1-hexanol 
were linear with respect to concentration in the range from 10 
nmol to 200 nmol and 100 nmol to 1000 nmol, respectively. 
Cyclohexene, the major product formed from cyclohexane 
carboxaldehyde, and cyclohexane, a minor product, were de- 
termined by gas chromatography of the head space of reaction 
mixtures that had been incubated in septum-sealed reaction 
vials. At the end of the incubation the vial was cooled in an 
ice-water bath and 0.1 ml of 30% perchloric acid was injected 
to quench the reaction. The vial was then heated at 60?C for 
20 min and 1.0 ml of the head space gas was removed with a 
gas-tight syringe and injected onto a 6-ft Supelco 60/80 
Carbopack B column containing 4% Carbowax 20M and 0.8% 
KOH. The carrier gas was helium at a flow rate of 27 ml/min. 
The column was maintained at 130?C for 7 min and the 
temperature was then raised to 210?C for 10 min. Cyclohexane 
and cyclohexene were eluted at 4.7 and 5.4 min, respectively. 
Standards were run in an identical manner; peak areas were 
linear over a concentration range from 0.2 to 2.0 nmol for both 
hydrocarbons. NADPH disappearance was measured by the 
decrease in absorbance at 340 nm. For the determination of 
H202, reactions were quenched with 0.2 ml of 45% trichloro- 
acetic acid, followed by centrifugation to remove the precip- 
itated material, and 1.0 ml of the supernatant solution was used 
for the determination of peroxide according to the method of 
Hildebrandt et al. (41). Under these conditions, NADPH 
disappearance, H202 formation, and the appearance of oxi- 
dation products from a series of substrates were all linear with 
time. In control experiments, P450 was omitted from the 
reaction mixtures or added after it had been heat-inactivated. 
Rate constants for initial electron transfer and binding con- 
stants for benzphetamine were determined according to pub- 
lished procedures (42, 43). The results presented in the tables 
are from an average of two or more experiments. 
RESULTS AND DISCUSSION 
We chose to examine the effect of mutagenesis on truncated 
P450 2B4, which we are studying with respect to membrane 
targeting, rather than on the full-length protein. Use of the 
fusion protein with glutathione-S-transferase (37) along with 
the thrombin cleavage methodology allows for rapid purifica- 
tion of the expressed cytochrome so that about 100 nmol of 
purified P450 2B4 (A2-27) or the 2B4 (A2-27) T302A mutant 
are routinely obtained from a 1-liter culture of E. coli MV1304 
cells. As noted in an earlier study, the truncated 2B4 retains the 
ability to function as a monooxygenase with all substrates 
examined, but the activities were found to be between 35 and 
80% of those of the full-length protein in the various reactions 
(37). The reason for the somewhat lower activity of the 
truncated protein is at present unclear. A comparable NH2- 
terminal truncation of P450 2E1 was shown previously to have 
no effect on the catalytic activity (44, 45). In the present study 
the mutation of threonine-302 to alanine resulted in no 
significant alteration in the ferric UV/visible spectrum or of 
the carbon monoxide difference spectrum of the 2B4 (A2-27) 
and the 2B4 (A2-27) T302A proteins relative to that of the 
purified liver microsomal "wild-type" 2B4 protein (data not 
shown). 
The rates of NADPH oxidation and H202 formation were 
measured in the absence of a substrate and in the presence of 
benzphetamine, 1-phenylethanol, cyclohexane, or cyclohexane 
carboxaldehyde with the three forms of 2B4 in a reconstituted 
system, as shown in Table 1. Electron transfer, as judged by 
NADPH oxidation, was more rapid when any of the substrates 
was added to the system containing any of the three cyto- 
chromes. Particularly striking was the effect of benzphetamine, 
with an increase of more than 7-fold in the rate of NADPH 
consumption with the full-length enzyme. The truncated pro- 
teins generally catalyzed NADPH oxidation at a decreased 
rate as compared to intact 2B4, the only exception being the 
T302A mutant with no substrate present. With each protein 
the rate of peroxide formation was also generally increased 
with a substrate present, except for 1-phenylethanol and 
cyclohexane carboxaldehyde with P450 2B4 (A2-27). Trunca- 
Table 2. Rates of substrate oxidation by P450 2B4 and variants in the reconstituted enzyme system 
Reaction rate, nmol/min per nmol of P450 
Product 2B4 (A2-27) 
Substrate determined 2B4 2B4 (A2--27) T302A 
Benzphetamine Formaldehyde 53.0 + 2.0 27.0 + 0.4 3.0 + 0.2 
1-Phenylethanol Acetophenone 18.4 + 0.3 4.0 + 0.0 2.5 + 0.0 
Cyclohexane Cyclohexanol 20.0 ? 0.2 4.4 + 0.7 1.0 + 0.1 
Cyclohexane carboxaldehyde Cyclohexene 0.27 ? 0.0 0.15 + 0.0 1.47 + 0.1 
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Table 3. Initial rates of electron transfer and substrate binding 
constants for P450 cytochromes 
Rate constant 
for P450 Binding 
reduction constant 
P450 Substrate (k), min-1 (Ks), mM 
2B4 None 375 + 15 
1-Phenylethanol 334 + 25 
Benzphetamine 210 + 20 
2B4 (A2-27) None 363 + 08 
1-Phenylethanol 353 + 18 
Benzphetamine 135 + 15 
2B4 (A2-27) None 366 + 12 
T302A 1-Phenylethanol 339 + 19 
Benzphetamine 150 + 12 
tion alone of 2B4 gave no increase in peroxide formation with 
or without a substrate present. Perhaps the most pertinent 
comparison from these results is the effect on the truncated 
enzyme of replacement of l;hreonine-302 by alanine, which 
without substrate present resulted in a 1.6-fold increase in 
NADPH oxidation but no increase in peroxide production, and 
with substrates present gave variable effects on NADPH 
consumption but consistent increases in the yield of peroxide, 
ranging from 1.6- to 2.5-fold with the four substrates examined. 
As indicated in Table 2, 2B4 (A2-27) is approximately 20 to 
50% as active as the full-length enzyme in the N-demethylation 
of benzphetamine, the oxygenation of cyclohexane and 1-phe- 
nylethanol to give cyclohexanol and acetophenone, respec- 
tively, and the deformylation of cyclohexane carboxaldehyde 
to yield cyclohexene. This is consistent with previous results 
with several substrates, including N,N-dimethylaniline and 
p-nitrophenetole (37). The most important comparison, how- 
ever, is of the reaction rates with the truncated cytochrome and 
the corresponding T302A mutant. The replacement of the 
threonine residue reduced the activities with benzphetamine, 
cyclohexane, and phenylethanol to one-ninth, one-fourth, and 
one-half, respectively. In this connection, generation of the 
iron-oxene oxidant is believed to require protonation of the 
iron-peroxy intermediate for cleavage of the 0-0 bond, as 
stated above, and additionally, Brinigar et al. (46) showed some 
years ago that heme-dioxygen complexes are unstable in protic 
solvents and are rapidly autoxidized, presumably due to pro- 
tonation of the oxygen. Thus, solvent protons in the active site 
could strongly influence the course of reactions of the heme- 
peroxy intermediate. Raag et al. (18) have concluded from 
analysis of the structures of P450cam and its T252A variant that 
the greater availability of solvent protons in the latter protein 
is probably responsible for the uncoupling and that a highly 
orchestrated protonation of the iron-peroxy intermediate must 
occur at the active site to generate the iron-oxene species. A 
recent study by Miller and White (47) suggests that P450 2B4 
retains water in the active site even in the presence of a 
hydrophobic substrate, which may account for the partial 
uncoupling observed with this enzyme. Alternatively, the 
solvent may serve as a protic source for cleavage of the 0-0 
bond, partially substituting for threonine-302 in 2B4 (A2-27) 
T302A. This may account for the remaining slight activity in 
the benzphetamine and cyclohexane hydroxylation reactions 
catalyzed by the mutant enzyme. In the case of 1-phenyletha- 
nol oxidation to acetophenone, however, a reaction known to 
occur via hydroxylation of the benzylic carbon (40), as much 
as one-half of the activity is retained by our T302A mutant. It 
may be noted in this connection that P45OEryF, which is highly 
unusual in lacking the conserved threonine in the active site, 
is competent in the hydroxylation of the erythromycin precur- 
sor 6-deoxyerythronolide B (26). From such substrate struc- 
ture-function relationships and analysis of the crystal structure 
of P45OEryF (48), Poulos and colleagues (49) have suggested 
that a novel substrate-assisted acid catalysis is used in the 
oxygen activation step. Presumably, a substrate hydroxyl group 
in conjunction with ordered water in the active site may 
provide the necessary hydrogen bonding network between the 
active site and the bulk solvent such that a proton can be 
provided for cleavage of the iron-peroxo complex to generate 
the iron-oxene species. Thus, we propose that in a similar way 
the hydroxyl group of 1-phenylethanol in conjunction with 
water molecules in the active site may replace the proton 
delivery network disrupted by the T302A mutation in P450 
2B4 (A2-27). It should also be noted that while the oxidation 
of 1-phenylethanol was demonstrated to proceed by a stepwise 
hydrogen atom abstraction and oxygen rebound mechanism, 
the oxidant was assumed to be an iron-oxenoid species (40). 
From our results it is apparent that threonine-302, while 
influencing the generation of the active oxidant for hydroxy- 
lation reactions, appears not to be uniquely responsible for 
promoting cleavage of the 0-0 bond of the iron-peroxo 
intermediate to the iron-oxenoid species. 
In sharp contrast to the decreased oxidation of benzphet- 
amine, cyclohexane, and I-phenylethanol by the T302A mu- 
tant, the deformylation of cyclohexane carboxaldehyde to yield 
cyclohexene was increased about 10-fold over that of truncated 
2B4 and more than 5-fold over that of intact 2B4 (Table 2). On 
the basis of this finding and that of previous studies with H202 
and artificial oxidants (14), we conclude that the reaction 
H 5+ ~RH 14 ____ H20 [Fe=O]5+- [Fe-OH]4+[Re] - Fe3+ + ROH 
2H+ 
2e- / Fe + 02 - Fe O 
CHO v Fe 
FFebJ 0 ' ?1H F e3+ + + HC-O + OH 
FIG. 1. Proposed scheme showing alternative routes for substrate oxidation by cytochrome P450, where Fe represents the heme iron atom at 
the active site, RH a substrate, and ROH the corresponding product in the oxenoid-supported pathway. Cyclohexane carboxaldehyde, a typical 
carbonyl substrate in the peroxide-supported pathway, is shown as producing a peroxyhemiacetal intermediate that yields formate with desaturation 
in the remaining structure. 
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involves peroxy-iron rather than oxenoid-iron as the active 
oxidant. It is important o note that the decreased oxidation of 
benzphetamine, I-phenylethanol, and cyclohexane by the 
T302A mutant is not due to a decreased rate of reduction of 
ferric P450 or poor substrate binding, as indicated by the 
results presented in Table 3. In additional experiments not 
presented here, the E301L and T303A mutants of the trun- 
cated 2B4 P450 were expressed in E. coli and purified. The 301 
mutant had little activity in all of the reactions examined and 
the 303 mutant was comparable to the truncated 2B4 in its 
activity. Of particular interest, neither of these variants dis- 
played the higher activity in aldehyde deformylation reported 
here for the T302A protein (H. M. Peng, personal communi- 
cation). 
As shown in the accompanying scheme (Fig. 1), a critical 
difference between the two pathways is the requirement for 
protons at the active site for cleavage of the oxygen-oxygen 
bond in the oxenoid route that results in the hydroxylation of 
a substrate, RH, to form ROH, but not for the deformylation- 
desaturation reaction with an aldehyde when peroxide serves 
as the direct oxygen donor. Thus, when the usual route for 
protonation of the iron-peroxide intermediate in the active site 
is perturbed, as with the T302A mutant, the proportion of the 
enzyme in the iron-peroxide state is presumably increased and 
reactions are favored that utilize this species. In this connec- 
tion, an investigation by Swinney and Mak (12) on solvent 
isotope effects on the 17av-hydroxylase and 17,20-lyase activ- 
ities of progesterone 17-hydroxylase-17,20-lyase is particularly 
relevant. D20 was found to promote the lytic over the hy- 
droxylation activity, consistent with a greater proportion of the 
iron-peroxy form of the oxidant being present due to weaker 
hydrogen ion activity in D20. 
Our results indicate that threonine-302 plays a central role 
in P450 2B4 in determining the relative rates of various 
oxygenating reactions catalyzed by this cytochrome. It remains 
to be established which of the many reactions now known to 
be catalyzed by P450 require the peroxo-iron intermediate as 
the direct oxygen donor and which of the many isoforms of this 
cytochrome make use of the peroxo-iron and oxenoid-iron 
species as alternative oxygenating agents. 
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